Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Suganthi Nanthakumar"'
Autor:
Jeremy Green, Upul K. Bandarage, Craig Marhefka, Suganthi Nanthakumar, Jon H. Come, Huai Gao, Jingrong Cao, Marc Jacobs, John J. Court
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 28:2622-2626
Rho kinase (ROCK) inhibitors are potential therapeutic agents for the treatment of a variety of disorders including hypertension, glaucoma and erectile dysfunction. Here we disclose a series of potent and selective ROCK inhibitors based on a substitu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d75421bd28516673f2638a022e494e4b
https://doi.org/10.1016/j.bmcl.2018.06.040
https://doi.org/10.1016/j.bmcl.2018.06.040
Autor:
Jianglin Liang, Robert J. Davies, James P. Griffith, Hardwin O'dowd, Cameron Stuver Moody, Elaine Krueger, Philip N. Collier, Yusheng Liao, Upul K. Bandarage, Alex Aronov, Jian Wang, Jingrong Cao, Derek B. Lowe, Veronique Damagnez, Elaine Y. Chin, John D. Doran, Emmanuelle Sizensky, Wojciech Dworakowski, Sudipta Mahajan, David D. Deininger, Marc Jacobs, Jinwang Xu, Arnaud Le Tiran, Suvarna Khare-Pandit, Albert C. Pierce, Suganthi Nanthakumar, Ron Grey, David Messersmith, James A. Henderson, Jon H. Come
Publikováno v:
Journal of Medicinal Chemistry. 61:5245-5256
The lipid kinase phosphoinositide 3-kinase γ (PI3Kγ) has attracted attention as a potential target to treat a variety of autoimmune disorders, including multiple sclerosis, due to its role in immune modulation and microglial activation. By minimizi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bd9109c79e1ecbf0788c161384fe50c
https://doi.org/10.1021/acs.jmedchem.8b00085
https://doi.org/10.1021/acs.jmedchem.8b00085
Autor:
Brian S. Luisi, Philip N. Collier, Pan Li, Lauffer David J, Qing Tang, Carl Poisson, Waal Nathan D, Ganesh Iyer, John J. Court, Sanjoy Kumar Das, Olivier Nicolas, B. Govinda Rao, Rebecca S. Shawgo, Laval C. Chan, Steven M. Ronkin, Nathalie Chauret, Suganthi Nanthakumar, Lucille L’Heureux, Darius Bilimoria, Nagraj Mani, Subajini Selliah, Francois Denis, Kishan Chandupatla, Constantin Yannopoulos, Warren Dorsch, Jeremy Green, Andrzej Ardzinski
Publikováno v:
Journal of medicinal chemistry. 59(13)
The hepatitis C viral proteins NS3/4A protease, NS5B polymerase, and NS5A are clinically validated targets for direct-acting antiviral therapies. The NS5B polymerase may be inhibited directly through the action of nucleosides or nucleotide analogues
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa0c3c4abca1dd4ed1cafe1b1f29b4e7
https://pubmed.ncbi.nlm.nih.gov/27366941
https://pubmed.ncbi.nlm.nih.gov/27366941